Result: One individual that was infected through homosexual contact, exhibited a high level of resistance to nelfinavir with ritonavir (NFV/r) with a D30N mutation and conferred intermediate resistance to all nucleoside reverse transcriptase inhibitors (NRTIs) with T69ins.
Table: D30N
Persistence of HIV-1 transmitted drug resistance mutations.
PMID: 23904291
2013
The Journal of infectious diseases
Table: D30N
Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
PMID: 23590295
2013
Journal of medicinal chemistry
Introduction: Recently, we characterized a clinically derived HIV-1 protease (PR20) bearing 20 mutations [Q7K, L10F, I13V, I15V, D30N, V32I, L33F, E35D, M36I, S37N, I47V, I54L, Q58E, I62V, L63P, A71V, I84V, N88D, L89T and L90M] and extremely resist
Emergence of drug resistance-associated mutations in HIV-1 subtype C protease gene in north India.
Result: D30N is the only mutation of a charged first shell residue in PR20 and second shell mutation N88D may compensate for the altered charge.
Result: Also, in vitro studies show that combining the two mutations D30N and L90M results in PR that exhibits high levels of resistance to nelfinavir.
Result: Analysis of mutation patterns in eight thousand and sixty virus isolates reveals that N88D is positively associated with D30N, and facilitates the occurrence of major resistance mutations D30N and L90M resulting in multidrug resistance.
Result: First, mutation of four (D30N, PMID: 24348205
2012
Journal of chemical theory and computation
Method: For example, LP1'Fp1-p6D30N/N88D denotes a complex of D30N/N88D PR variant with the LP1T mutant of the p1-p6 cleavage site, where LP1'F refers to a Leu-to-Phe mutation at P1' position of the cleavage site.
Method: HIV-1 PR (WT, V82A, or D30N/N88D) and the cleavage site (AP2V, LP1'F, or SP3'N) variants in a PR:substrate complex are designated by a subscript and a superscript to the name of the cleavage site.
Result: Compared to the WTp1-p6WT complex, P1 and P1' in SP3'Np1-p6D30N/n88D h
Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.
PMID: 22239286
2012
The journal of physical chemistry. B
Introduction: As for other approved PIs, several HIV-pr mutants were demonstrated to have drug resistance over the TMC114, like D30N and I50V, whereas L90M is well adapted by the TMC114.
Introduction: It was found that loss of H-bonds between Asp30 and TMC114 drives the drug resistance in D30N, whereas for I50V it is the increased polar solvation energies for the two residues Asp30' and Val50'.
Introduction: The drug resistance mechanism of such mutants was explored at the molecular level with all-atomistic MD simulation combined with molecular mechanics-Poisson/Boltzmann surface area (MM-PBSA) for the binding energies of TMC114 to D30N
Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Abstract: The most common UDS-detected DRM were NRTI in 18 subjects: M184V/I (11), TAMs(7) & K65R(4); PI DRMs were detected in 9 subjects: M46I/V(5), F53L(2), I50V(1), D30N(1), and N88S(1).
Result: Nineteen of 24 (79.2%) had any PI, N(t)RTI and/or NNRTI resistance mutations; 18/24 (75%) had N(t)RTI mutations: M184V/I (11), TAMs(7) and K65R (4), and 9/24 (37.5%) had PI mutations:
Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naive Population from Northern India.
Abstract: One patient had a major RT mutation M184V, known to confer resistance to lamivudine, and another had a major protease inhibitor (PI) mutation D30N that imparts resistance to nelfinavir.
Result: One patient (1.47%) had RT mutation, M184V that imparts resistance to NRTIs, lamivudine, and emtricitabine, and another (1.47%) had a major PI mutation, D30N, conferring resistance to nelfinavir.
Discussion: One participant (1.5%) in our study had a major PI mutation, D30N, in the protease gene.
Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City.
PMID: 22592583
2012
Journal of acquired immune deficiency syndromes (1999)
4Method: ARV resistance was defined by mutations at the following positions: M41L, A62V, K65R, D67N, T69ins, K70R, L74VI, Y115F, F116Y, Q151M, M184VI, T210W, T215YF and K219QE for Nucleoside Reverse Transcriptase Inhibitors (NRTI), L100I, K101EP, K103NS, V106AM
HIV mutation literature information.
PMID: 
2013
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT